AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

CVS GROUP PLC

Transaction in Own Shares Dec 19, 2025

7590_pos_2025-12-19_c3c4d223-20d2-41db-90f6-ca6f378bcf46.html

Transaction in Own Shares

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 2129M

CVS Group plc

19 December 2025

19 December 2025

CVS GROUP plc

("CVS" or the "Company" and, together with its subsidiaries, the "Group")

Transaction in own shares

CVS announces that on 18 December 2025 it purchased the following number of its ordinary shares of 0.2 pence each ("Ordinary Shares") from Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg"), in accordance with the terms of the share buyback programme announced on 24 October 2025 (the "Share Buyback Programme").

Date of purchase: 18/12/2025
Aggregate number of Ordinary Shares purchased: 18,123
Lowest price paid per share (GBp): 1,248.00
Highest price paid per share (GBp): 1,268.00
Volume weighted average price paid per share (GBp): 1,257.38

CVS intends to cancel all of the purchased Ordinary Shares.

Following settlement of the above purchases and cancellation of the Ordinary Shares purchased, CVS will have 70,783,372 Ordinary Shares in issue and holds no Ordinary Shares in treasury.

The total number of voting rights in CVS is therefore 70,783,372 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, CVS under the Financial Conduct Authority's Disclosure and Transparency Rules.

Since the commencement of the Share Buyback Programme, the Company has repurchased 957,411 Ordinary Shares in aggregate at a weighted average price of 1,217.39 pence per share.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018, the table below contains detailed information of the individual trades made by Berenberg as part of the Share Buyback Programme.

Individual transactions:

Number of

Ordinary Shares purchased
Transaction price (GBp share) Time of

transaction (UK Time)
Transaction

reference number
Trading Venue
307 1250 18/12/2025 08:09:43 1353937584130558 XLON
102 1254 18/12/2025 08:37:43 1353937584133303 XLON
8 1254 18/12/2025 08:37:43 1353937584133304 XLON
453 1254 18/12/2025 08:37:43 1353937584133305 XLON
609 1262 18/12/2025 09:02:37 1353937584135463 XLON
255 1262 18/12/2025 09:02:37 1353937584135464 XLON
870 1264 18/12/2025 09:10:39 1353937584135960 XLON
228 1264 18/12/2025 09:16:40 1353937584136294 XLON
869 1262 18/12/2025 09:30:28 1353937584137015 XLON
760 1262 18/12/2025 09:30:28 1353937584137016 XLON
72 1258 18/12/2025 09:33:10 1353937584137105 XLON
174 1260 18/12/2025 09:57:19 1353937584138818 XLON
80 1258 18/12/2025 09:57:19 1353937584138822 XLON
70 1262 18/12/2025 10:14:15 1353937584139761 XLON
106 1260 18/12/2025 11:06:58 1353937584142803 XLON
81 1258 18/12/2025 11:38:14 1353937584143948 XLON
146 1258 18/12/2025 11:38:14 1353937584143951 XLON
105 1254 18/12/2025 11:45:05 1353937584144245 XLON
727 1252 18/12/2025 11:49:35 1353937584144455 XLON
328 1252 18/12/2025 11:49:39 1353937584144460 XLON
101 1252 18/12/2025 11:49:51 1353937584144475 XLON
774 1252 18/12/2025 11:49:54 1353937584144486 XLON
900 1250 18/12/2025 11:51:00 1353937584144598 XLON
908 1254 18/12/2025 11:59:04 1353937584144923 XLON
908 1254 18/12/2025 11:59:04 1353937584144932 XLON
901 1250 18/12/2025 12:00:26 1353937584145643 XLON
429 1250 18/12/2025 12:02:30 1353937584147471 XLON
376 1250 18/12/2025 12:02:30 1353937584147473 XLON
590 1250 18/12/2025 12:05:55 1353937584147883 XLON
622 1248 18/12/2025 12:07:00 1353937584148033 XLON
87 1248 18/12/2025 12:07:00 1353937584148034 XLON
300 1248 18/12/2025 12:13:16 1353937584149101 XLON
869 1258 18/12/2025 13:44:50 1353937584156800 XLON
376 1262 18/12/2025 14:29:32 1353937584160096 XLON
100 1260 18/12/2025 14:30:01 1353937584160298 XLON
793 1268 18/12/2025 14:55:35 1353937584164955 XLON
275 1268 18/12/2025 14:55:35 1353937584164956 XLON
275 1264 18/12/2025 15:07:55 1353937584166713 XLON
267 1264 18/12/2025 15:21:43 1353937584168395 XLON
100 1264 18/12/2025 15:21:43 1353937584168397 XLON
192 1264 18/12/2025 15:41:00 1353937584171506 XLON
144 1264 18/12/2025 15:41:00 1353937584171507 XLON
201 1264 18/12/2025 16:03:50 1353937584175041 XLON
198 1264 18/12/2025 16:03:54 1353937584175064 XLON
6 1268 18/12/2025 16:19:05 1353937584177834 XLON
258 1268 18/12/2025 16:22:43 1353937584178435 XLON
32 1268 18/12/2025 16:22:43 1353937584178436 XLON
25 1268 18/12/2025 16:22:43 1353937584178437 XLON
549 1268 18/12/2025 16:22:43 1353937584178438 XLON
217 1266 18/12/2025 16:23:21 1353937584178537 XLON

Contacts

CVS Group plc                                                                                                                                                 via Camarco

Richard Fairman, CEO

Robin Alfonso, CFO

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

Peel Hunt LLP (Nominated Adviser & Joint Broker)                                                                                 +44 (0)20 7418 8900

Christopher Golden / James Steel / Andrew Clark

Berenberg (Joint Broker)                                                                                                                             +44 (0)20 3207 7800

Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing

Camarco (Financial PR)                                                                                                                           [email protected]

Ginny Pulbrook                                                                                                                                                +44 (0)7961 315 138

Letaba Rimell

Tilly Butcher

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is an AIM-listed provider of veterinary services with operations in the UK and Australia.  CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group now operates c.470 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

POSGPGMPPUPAUUB

Talk to a Data Expert

Have a question? We'll get back to you promptly.